coronavirus vaccine to focus on enrolling at-risk minorities, even if that slows down the trial speed, the company said on Friday.
Death rates for people of colour in U.S. skyrocketed amid coronavirus, study finds Shares of Moderna, one of the few companies in the final stages of developing a safe and effective COVID-19 vaccine, closed down about 3.5%.The company said it has enrolled 21,411 participants in the study so far.
It had 17,000 participants as of last week, with 24% from communities of color.The drug developer aims to recruit 30,000 healthy volunteers and said it expected enrollment in the late-stage study, which began in late-July, to be completed in September.A growing body of evidence has shown that long-standing health and.